NovaBridge Biosciences American Depositary Shares (NBP)
FairStock Score: 32/100 — RISKY
Key Financials
| Current Price | $1.22 |
| Market Cap | $287M |
| P/E Ratio | -1.76 |
| ROE | -59.1% |
| Dividend Yield | —% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
As a Graham-and-Buffett-style investor, I start with business quality. NovaBridge is a 30-employee immuno-oncology biotech with a Phase 2 CLDN18.2 bispecific program and an ophthalmology segment. That is an early-stage pipeline, not a demonstrated franchise; I see no durable moat in the supplied figures. Financial health is poor. FairStock's trailing FCF is -$15.3M, FCF yield -5.3%, ROE -59.10%, ROCE -34.98%, Piotroski F-score 1/9, and Altman Z-score -1.74. The one balance-sheet comfort is D/E of 0.02, so debt is not the immediate problem; cash burn is. Valuation is tricky. At the $1.22 close on 2026-10-26, market cap is $286.8M, P/B is 0.70 and P/E is -1.76, both FairStock calculations. A sub-book price can look cheap, but with negative earnings and weak quality scores it may be a value trap rather than a bargain. The stock sits near the bottom of its $1.21-$5.19 52-week range and has beta 1.50, so the market has already marked it as risky. Growth trajectory is unproven: the supplied revenue-growth figure is not available, and no multi-year filed record exists to judge it. FairStock's Lynch category is none because there are zero years of filed results versus the three needed. I would need clinical progress, controlled cash burn, and a longer filed record before calling this a business with a margin of safety.
In plain English: NovaBridge is a small biotech company working on cancer treatments. It is losing money, has no revenue growth figure in the supplied data, and its financial health scores are weak. At $1.22, the price is near the bottom of its yearly range, so it looks low, but the losses make it a risky, unproven business rather than an obvious bargain.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer